Skip to main content

Year: 2025

Franklin Electric Reports Third Quarter 2025 Results

Third Quarter 2025 HighlightsConsolidated net sales of $581.7 million, an increase of 9% to the prior year Net sales increased across all three segments; 11% in Water Systems, 15% in Energy Systems, and 3% in Distribution Operating income was $85.1 million, an increase of 16% to the prior year, with operating margin of 14.6% The company terminated its US Pension Plan for a pre-tax settlement charge of $55.3 million ($41.7 million net of tax) and an EPS impact of approximately $0.93 per share net of tax GAAP fully diluted earnings per share (EPS) was $0.37FORT WAYNE, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) — Franklin Electric Co., Inc. today announced its third quarter financial results for fiscal year 2025. Third quarter 2025 net sales were $581.7 million compared to third quarter 2024 net sales of $531.4 million. Third quarter...

Continue reading

Uni-Fuels Announces 2025 Interim Financial Results

Strong Operational Performance Drives Revenue and Gross Profit Growth SINGAPORE, Oct. 28, 2025 (GLOBE NEWSWIRE) — Uni-Fuels Holdings Limited (NASDAQ: UFG), (“Uni-Fuels” or the “Company”), a global provider of marine fuel solutions headquartered in Singapore, today announced its interim financial results for the six months ended June 30, 2025. Key Strategic Developments        On February 12, 2025, the Company’s wholly owned subsidiary, Uni-Fuels Pte Ltd (“Uni-Fuels Singapore”), received ISCC EU and ISCC PLUS certifications from the International Sustainability and Carbon Certification (“ISCC”). The ISCC certifications ensure that the biofuels traded by Uni-Fuels Singapore meet the requirements of the European Union’s (“EU”) Renewable Energy Directive (“RED II”), including the provision of Proof of Sustainability (“POS”). On April...

Continue reading

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois. The presentation will feature clinical data from the recently announced Phase IIa (ENX-CL-05-001) 3-month topline data readout for Allocetra™ in patients with moderate-to-severe knee osteoarthritis (KOA), including clinically meaningful and statistically significant improvement compared to the control placebo arm in reduction of pain and improvement of function, in idiopathic age-related osteoarthritis patients (≥60 years), representing...

Continue reading

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Vancouver, Canada, Oct. 28, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, is proud to announce that its CEO, Dr. Adi Zuloff-Shani, will participate as a featured speaker at the upcoming “Women in Psychedelic Leadership: Driving Innovation & Governance” webinar. The event, hosted by the Psychedelic Association of Canada, is scheduled for October 29, 2025, at 9:00 AM PT/noon ET, and will be accessible online via Eventbrite. Dr. Zuloff-Shani, a biomedical research and development executive with over 20 years of experience in the healthcare industry, brings a wealth of knowledge in therapeutics...

Continue reading

Inseego Redefines Enterprise 5G Fixed Wireless Access (FWA) with the FX4200 Cellular Router and Inseego Connect SaaS

New 5G solution bridges the gap between overbuilt network complexity and plug-n-play simplicity to deliver powerful, enterprise-class wireless connectivity for small- and mid-size enterprisesSAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) — Inseego Corp. (Nasdaq: INSG), a global leader in 5G mobile broadband and 5G fixed wireless access (FWA) solutions, today introduced a new approach to enterprise FWA with a completely new 5G hardware platform, the Inseego® Wavemaker FX4200, and updated software suite, Inseego Connect. Designed to bridge the gap between performance and ease-of-use for enterprise wireless networks, this innovative approach to FWA pairs the power and functionality of enterprise network solutions with the simplicity and ease-of-management of small- and medium-sized (SMB)-oriented solutions. “In order to take advantage...

Continue reading

NAPC Defense Accelerates Expansion with Major Interest from Saudi Arabia, Jordan, Kuwait, and Pakistan

Moves are Part of NAPC’s Accelerating Domestic and International ExpansionThe CornerShot in useLARGO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) — NAPC Defense, Inc. (OTCID:BLIS) (“NAPC” or “the Company”), a licensed broker of munitions and military and enforcement, for military and law enforcement worldwide, is pleased to announce it is nearing the final demonstration of its CornerShot tactical system for the Land Forces of Saudi Arabia, following over a year of dedicated sales and engagement activity both in Saudi Arabia and now at its Florida facility. The demonstration, initially slated for this quarter, was delayed due to the recent U.S. government shutdown and associated security, customs, and logistical complications. Nonetheless, NAPC expects this event to unlock a significant multi-million-dollar contract...

Continue reading

Sysco Reports First Quarter 2026 Results; Reiterates FY26 Guidance

HOUSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY) (“Sysco” or the “company”) today announced financial results for its 13-week first fiscal quarter ended September 27, 2025. Key financial results for the first quarter of fiscal year 2026 include the following (comparisons are to the same period in fiscal year 2025):Sales increased 3.2%; U.S. Foodservice volume increased 0.1%; Gross profit increased 3.9% to $3.9 billion; Operating income decreased 1.0% to $800 million, and adjusted operating income increased 2.9% to $898 million1; Net earnings decreased 2.9% to $476 million, and adjusted net earnings increased 2.0% to $551 million1; EBITDA decreased 3.1% to $1.0 billion2, and adjusted EBITDA increased 0.1% to $1.1 billion1,2; and EPS3 remained flat at $0.99, and adjusted EPS1 increased 5.5% to $1.15.“We...

Continue reading

Independent Bank Corporation Reports 2025 Third Quarter Results

Third Quarter Highlights Highlights for the third quarter of 2025 include:Increase in net interest income of $0.7 million (or 1.7%) over the second quarter of 2025; Increase in tangible common equity per share of common stock of $1.06 (or 20.0% annualized) from June 30, 2025; Net growth in total deposits, less brokered time deposits of $148.2 million (or 13.0% annualized) from June 30, 2025; Net growth in loans of $33.9 million (or 3.2% annualized) from June 30, 2025; and The payment of a 26 cent per share dividend on common stock on August 15, 2025.GRAND RAPIDS, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP) reported third quarter 2025 net income of $17.5 million, or $0.84 per diluted share, versus net income of $13.8 million, or $0.65 per diluted share, in the prior-year period. William...

Continue reading

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 – $675 million –– KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2025 financial results and recent portfolio execution. “Year to date, ARCALYST revenue has continued to grow, with the expanding adoption of IL-1α...

Continue reading

Hubbell Reports Third Quarter 2025 Results

Shelton, CT, Oct. 28, 2025 (GLOBE NEWSWIRE) — HUBBELL REPORTS THIRD QUARTER 2025 RESULTS 3Q diluted EPS of $4.77; adjusted diluted EPS of $5.17 3Q net sales +4% (organic +3%) 3Q operating margin 22.0%; adjusted operating margin 23.9% Raising 2025 diluted EPS outlook to $16.55-$16.75; adj. diluted EPS of $18.10-$18.30Hubbell Incorporated (NYSE: HUBB) today reported operating results for the third quarter ended September 30, 2025. “Hubbell delivered double digit adjusted earnings per diluted share growth in the third quarter, driven by strong organic growth in Electrical Solutions and Grid Infrastructure products within our Utility Solutions segment, as well as a lower year-over-year tax rate” said Gerben Bakker, Chairman, President and CEO. Mr. Bakker continued, “In our Utility Solutions segment, Grid Infrastructure achieved...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.